Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
about
Canagliflozin Treatment in Patients with Type 2 Diabetes MellitusSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic AgentsClinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.A Numbering System for MFS Transporter Proteins.In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.
P2860
Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Effects of rifampin, cyclospor ...... itor, in healthy participants.
@ast
Effects of rifampin, cyclospor ...... itor, in healthy participants.
@en
type
label
Effects of rifampin, cyclospor ...... itor, in healthy participants.
@ast
Effects of rifampin, cyclospor ...... itor, in healthy participants.
@en
prefLabel
Effects of rifampin, cyclospor ...... itor, in healthy participants.
@ast
Effects of rifampin, cyclospor ...... itor, in healthy participants.
@en
P2093
P2860
P356
P1476
Effects of rifampin, cyclospor ...... itor, in healthy participants.
@en
P2093
Christopher Curtin
Damayanthi Devineni
Hans Stieltjes
Jay Ariyawansa
Joe Murphy
Nicholas A Di Prospero
Nicole Vaccaro
Paul Rothenberg
Rao N V S Mamidi
P2860
P304
P356
10.5414/CP202158
P577
2015-02-01T00:00:00Z